Sana Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good afternoon from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce Sana Biotechnology and CEO, Steve Harr. Please note that following this presentation, we will move right into a Q&A session. (Operator Instructions) So with that, Steve, thanks for joining us today. Let me turn things over to you for an update.
Thank you, Cory, and thank you, everybody, for joining us today. We'll be making some forward-looking statements today, as you might imagine. So please do take a look at our 10-Q and 10-K. We spent a lot of time on the risk factors, so hope you'll find that useful.
So Sana was founded with the belief that one of, if not the most important transformation that will occur in medicine over the next several decades, is the ability to modulate genes and use cells as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
